BOOST-2随机安慰剂对照试验:心肌梗死后冠状动脉内自体骨髓细胞移植
BOOST-2是一项在德国和挪威10个中心进行的随机、安慰剂对照、双盲试验,纳入153例大面积ST段抬高型心肌梗死(STEMI)患者,在经皮冠状动脉介入治疗(PCI)后8.1±2.6天单次冠状动脉内输注安慰剂、高剂量或低剂量自体核骨髓细胞(BMCs)或经γ辐照的BMCs。主要终点为基线至6个月MRI测定的左室射血分数(LVEF)变化。高剂量BMCs组6个月LVEF增加4.3个百分点,对照组增加3.3个百分点,估计治疗效应为1.0个百分点(95%CI -2.6至4.7;P=0.57),低剂量BMCs治疗效应为0.5个百分点(-3.0至4.1;P=0.76),辐照BMCs亦无显著治疗效应。BMC输注安全,未伴随不良临床事件。结论:BOOST-2试验不支持在当前早期PCI和药物治疗标准下对STEMI伴中度LVEF降低患者使用核骨髓细胞。
要点
- 高剂量BMCs组6个月LVEF增加4.3个百分点,对照组增加3.3个百分点,治疗效应1.0个百分点(95%CI -2.6至4.7;P=0.57),未达统计学显著。
- 低剂量BMCs治疗效应0.5个百分点(95%CI -3.0至4.1;P=0.76),辐照BMCs亦无显著治疗效应。
- BMC输注安全,未伴随不良临床事件;BOOST-2不支持对STEMI伴中度LVEF降低患者使用核骨髓细胞。
核心结论
- BOOST-2试验不支持在当前早期PCI和药物治疗标准下对STEMI伴中度LVEF降低患者使用核骨髓细胞。
研究设计与样本
- 随机、安慰剂对照、双盲、多中心(德国和挪威10个中心)试验,采用多臂设计,纳入153例大面积STEMI患者。
- 患者随机接受单次冠状动脉内输注安慰剂(对照组)、高剂量BMCs、低剂量BMCs、经γ辐照的高剂量BMCs或经γ辐照的低剂量BMCs,输注时间为PCI后8.1±2.6天,并联合指南推荐的药物治疗。
- 主要终点为基线(细胞输注前)至6个月MRI测定的LVEF变化。
- 试验注册号:ISRCTN17457407;入组时间为2006年3月9日至2013年7月16日。
主要发现
- 总体人群基线LVEF为45.0±8.5%。
- 6个月时,对照组LVEF增加3.3个百分点,高剂量BMCs组增加4.3个百分点,估计治疗效应为1.0个百分点(95%CI -2.6至4.7;P=0.57)。
- 低剂量BMCs的治疗效应为0.5个百分点(95%CI -3.0至4.1;P=0.76)。
- 经γ辐照的BMCs亦无显著治疗效应。
- BMC输注安全,未伴随不良临床事件。
临床怎么用
- BOOST-2试验不支持在当前早期PCI和药物治疗标准下对STEMI伴中度LVEF降低患者使用核骨髓细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Intracoronary infusion of autologous nucleated bone marrow cells (BMCs) enhanced the recovery of left ventricular ejection fraction (LVEF) after ST-segment elevation myocardial infarction (STEMI) in the randomised-controlled, open-label BOOST trial. We reassessed the therapeutic potential of nucleated BMCs in the randomised placebo-controlled, double-blind BOOST-2 trial conducted in 10 centres in Germany and Norway. METHODS AND RESULTS: Using a multiple arm design, we investigated the dose-response relationship and explored whether γ-irradiation which eliminates the clonogenic potential of stem and progenitor cells has an impact on BMC efficacy. Between 9 March 2006 and 16 July 2013, 153 patients with large STEMI were randomly assigned to receive a single intracoronary infusion of placebo (control group), high-dose (hi)BMCs, low-dose (lo)BMCs, irradiated hiBMCs, or irradiated loBMCs 8.1 ± 2.6 days after percutaneous coronary intervention (PCI) in addition to guideline-recommended medical treatment. Change in LVEF from baseline (before cell infusion) to 6 months as determined by MRI was the primary endpoint. The trial is registered at Current Controlled Trials (ISRCTN17457407). Baseline LVEF was 45.0 ± 8.5% in the overall population. At 6 months, LVEF had increased by 3.3 percentage points in the control group and 4.3 percentage points in the hiBMC group. The estimated treatment effect was 1.0 percentage points (95% confidence interval, -2.6 to 4.7; P = 0.57). The treatment effect of loBMCs was 0.5 percentage points (-3.0 to 4.1; P = 0.76). Likewise, irradiated BMCs did not have significant treatment effects. BMC transfer was safe and not associated with adverse clinical events. CONCLUSION: The BOOST-2 trial does not support the use of nucleated BMCs in patients with STEMI and moderately reduced LVEF treated according to current standards of early PCI and drug therapy.
引用
- Wollert KC, Meyer GP, Müller-Ehmsen J, et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J. 2017. PMID: 28431003. doi:10.1093/eurheartj/ehx188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。